このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Hoth Therapeutics マネジメント

マネジメント基準チェック /44

Hoth Therapeutics'の CEO はRobb Knieで、 May2017年に任命され、の在任期間は 7.08年です。の年間総報酬は$ 868.82Kで、 51.8%給与と48.2%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.68%を直接所有しており、その価値は$ 30.15K 。経営陣と取締役会の平均在任期間はそれぞれ5.3年と4.3年です。

主要情報

Robb Knie

最高経営責任者

US$868.8k

報酬総額

CEO給与比率	51.8%
CEO在任期間	7.2yrs
CEOの所有権	0.7%
経営陣の平均在職期間	5.3yrs
取締役会の平均在任期間	4.4yrs

経営陣の近況

Recent updates

Hoth Therapeutics partners with Altasciences to manufacture HT-TBI for brain injury

Sep 20

Hoth Therapeutics granted grace days by Nasdaq to regain compliance with bid price rule

Jun 29

Hoth Therapeutics shares rise 10% on developmental plans for HT-KIT in multiple orphan diseases and rare cancers

May 03

Hoth provides pipeline and regulatory timeline update

Feb 02

FDA grants Hoth Therapeutics Pre-IND meeting for HT-001, shares up 15%

Jan 13

Hoth Therapeutics to initiate IND enabling studies of HT-001 in cancer

Jan 11

Hoth Therapeutics inks deal for treatment of multi-drug resistant bacterial lung infections, shares up 15%

Jan 04

Hoth therapeutics signs production agreement for HT-001, Shares up 75%

Dec 31

Companies Like Hoth Therapeutics (NASDAQ:HOTH) Could Be Quite Risky

Dec 02

Hoth Therapeutics shows encouraging preclinical action in autoimmune skin disorder

Nov 03

CEO報酬分析

Hoth Therapeutics の収益と比較して、Robb Knie の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$8m
Dec 31 2023	US$869k	US$450k	-US$8m
Sep 30 2023	n/a	n/a	-US$10m
Jun 30 2023	n/a	n/a	-US$10m
Mar 31 2023	n/a	n/a	-US$11m
Dec 31 2022	US$1m	US$450k	-US$11m
Sep 30 2022	n/a	n/a	-US$11m
Jun 30 2022	n/a	n/a	-US$12m
Mar 31 2022	n/a	n/a	-US$13m
Dec 31 2021	US$1m	US$400k	-US$14m
Sep 30 2021	n/a	n/a	-US$12m
Jun 30 2021	n/a	n/a	-US$10m
Mar 31 2021	n/a	n/a	-US$10m
Dec 31 2020	US$781k	US$350k	-US$7m
Sep 30 2020	n/a	n/a	-US$10m
Jun 30 2020	n/a	n/a	-US$10m
Mar 31 2020	n/a	n/a	-US$9m
Dec 31 2019	US$2m	US$350k	-US$8m
Sep 30 2019	n/a	n/a	-US$4m
Jun 30 2019	n/a	n/a	-US$3m
Mar 31 2019	n/a	n/a	-US$3m
Dec 31 2018	US$308k	US$250k	-US$2m
Sep 30 2018	n/a	n/a	-US$3m
Dec 31 2017	US$146k	US$146k	-US$3m

報酬と市場: Robbの総報酬 ($USD 868.82K ) は、 US市場 ($USD 678.50K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Robbの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Robb Knie (55 yo)

7.2yrs

在職期間

US$868,823

報酬

Mr. Robb Knie is Founder of Hoth Therapeutics, Inc. Mr. Knie served as the Chief Executive Officer, Chief Financial Officer and Chairman of the Board of Directors of FoxWayne Enterprises Acquisition Corp....

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Robb Knie	Founder	7.2yrs	US$868.82k	0.68% $ 33.0k
David Briones	Chief Financial Officer	5.3yrs	データなし	データなし
Hayley Springer	Executive Vice President of Operations	2.2yrs	データなし	データなし

5.3yrs

平均在職期間

経験豊富な経営陣: HOTHの経営陣は経験豊富で経験豊富です（平均在職期間は5.3年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Robb Knie	Founder	7.2yrs	US$868.82k	0.68% $ 33.0k
Adam Friedman	Member of Scientific Advisory Board	7yrs	データなし	データなし
Mario Lacouture	Member of Scientific Advisory Board	3.5yrs	データなし	データなし
David Sarnoff	Independent Director	5.9yrs	US$65.21k	0.020% $ 996.5
William Weglicki	Member of Scientific Advisory Board	4.6yrs	データなし	データなし
Wayne Linsley	Independent Director	4.3yrs	US$65.21k	0.0027% $ 133.5
Glenn Cruse	Member of Scientific Advisory Board	4.4yrs	データなし	データなし
Graig Springer	Independent Director	4.4yrs	US$65.21k	0.026% $ 1.2k
Sergio Traversa	Member of Scientific Advisory Board	no data	データなし	データなし
Jeff Pavell	Independent Director	1.6yrs	US$65.21k	0.10% $ 5.1k
John Cirrito	Member of Scientific Advisory Board	2.5yrs	データなし	データなし
Carla Yuede	Member of Scientific Advisory Board	2.5yrs	データなし	データなし

4.4yrs

平均在職期間

56yo

平均年齢

経験豊富なボード: HOTHの取締役会は経験豊富であると考えられます ( 4.3年の平均在任期間)。

Hoth Therapeutics マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Hoth Therapeutics, Inc., Annual General Meeting, Aug 07, 2024

Hoth Therapeutics, Inc., Annual General Meeting, Aug 18, 2023

Hoth Therapeutics, Inc. Announces Board Changes

High number of new and inexperienced directors

High number of new and inexperienced directors

Hoth Therapeutics, Inc. Announces Scientific Advisory Board Appointments

Recent updates

New major risk - Shareholder dilution

Hoth Therapeutics, Inc., Annual General Meeting, Aug 07, 2024

New major risk - Financial position

Hoth Therapeutics, Inc. Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ

Hoth Therapeutics Receives FDA Approval to Expand HT-001 Clinical Trial to Treat Severely III Patients

Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial for Cancer Patients of HT-001 At University of Miami

Hoth Therapeutics Announces Successfully Completed Manufacturing of its Cancer Fighting HT-KIT for Ind-Enabling Studies

Hoth Therapeutics, Inc. Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia

Price target decreased by 50% to US$9.50

Hoth Therapeutics, Inc. Doses First Patient in its Phase 2a Clinical Trial of HT-001 for Treatment of Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors

Hoth Therapeutics, Inc. Receives Protocol Approval for HT-001 Cancer Therapeutic

Hoth Therapeutics Announces Irb Approval for Fda Cleared First-In-Human Clinical Trial of Ht-001 At Second Clinical Site

New major risk - Share price stability

Hoth Therapeutics, Inc., Annual General Meeting, Aug 18, 2023

Algorithm Sciences, Inc. cancelled the acquisition of Hoth Therapeutics, Inc. (NasdaqCM:HOTH) in a reverse merger transaction.

Hoth Therapeutics Announces Increased Positive Results of its Alzheimer's Therapeutic HT-ALZ

Hoth Therapeutics, Inc. Announces Selection of First 3 Clinical Sites for its Phase 2 Clinical Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy

Price target decreased to US$19.00

Hoth Therapeutics, Inc. announced that it expects to receive $10 million in funding

Hoth Therapeutics, Inc. Announces Board Changes

High number of new and inexperienced directors

Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements

Hoth Therapeutics Reports Positive Biolexa Phase 1B Clinical Trial Results in Mild to Moderate Atopic Dermatitis

Hoth Therapeutics Announces 1:25 Reverse Stock Split to Regain Compliance

Hoth Therapeutics partners with Altasciences to manufacture HT-TBI for brain injury

Hoth Therapeutics, Inc. mRNA Frame-Shifting Therapeutic, HT-004, Shows Potential to Reduce Lung Inflammation in Asthma and Allergy Disorders

Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Cognitive Improvements in Alzheimer's Disease Mouse Model

Hoth Therapeutics Gets 180 Grace Days by Nasdaq to Regain Compliance with Bid Price Rule

Hoth Therapeutics granted grace days by Nasdaq to regain compliance with bid price rule

Hoth Therapeutics, Inc, Announces HREC Approval in Australia for Next Phase of Trial of BioLexa for Patients with Atopic Dermatitis

Price target decreased to US$3.00

Hoth Therapeutics, Inc. Announces Preliminary Efficacy Findings From Phase 1b Clinical Trial with Mild to Moderate Atopic Dermatitis Patient Cohort

Price target decreased to US$3.50

High number of new and inexperienced directors

Hoth Therapeutics, Inc. Announces Development Updates for Its Novel Cancer Therapeutic, HT-KIT

Forecast to breakeven in 2023

Forecast to breakeven in 2023

Hoth Therapeutics Announces Presentation of the HT-ALZ Proof-of-Concept Alzheimer's Disease Preclinical Data at the 2022 Alzheimer's Association International Conference

Hoth Therapeutics, Inc. Announces Scientific Advisory Board Appointments

Hoth Therapeutics, Inc. Begins Dosing to Investigate the Effect of HT-ALZ on Memory, Anxiety, and Executive Function

Hoth Therapeutics, Inc. Announces HT-ALZ Therapeutic Shows Positive Results - Reduce Amyloid ß in Alzheimer's Disease

Hoth Therapeutics, Inc Announces Submission of Orphan Drug Designation Request for HT-KIT to Treat Mastocytosis

Hoth Therapeutics' Enrollment and Dosing in Second Cohort in Phase 1b Human Trial for Atopic Dermatitis Under Way

Price target decreased to US$4.75

Here's Why We're Watching Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Situation

Hoth Therapeutics, Inc. Submits to Ethics Committee for Approval to Initiate Patient Cohort 2 in BioLexa Clinical Trial

Hoth Therapeutics, Inc. Announces Positive Phase 1b Results for Completed First Cohort of Patient Trial of BioLexa

Price target decreased to US$7.25

Hoth Therapeutics, Inc. Initiates Preclinical Study of HT-ALZ for Alzheimer's Disease

Hoth Therapeutics, Inc. Announces Positive Confirmatory Results from in Vivo Model of Ht-003 Assets as Potential Treatment Against Acne

Hoth Therapeutics extends agreement for experimental antibiotic

We're Not Very Worried About Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Rate

Hoth Therapeutics Shares Positive Preclinical Results of Novel HT-KIT Therapeutic

Hoth Therapeutics Announces Development of HT-KIT to Treat Multiple Orphan Diseases, Including Rare Cancers

Hoth Therapeutics expands research agreement with VCU for COVID-19 therapeutic

Hoth Therapeutics shares rise 10% on developmental plans for HT-KIT in multiple orphan diseases and rare cancers

Hoth Therapeutics Executes Agreement to Assess the Effect of HT-003 Therapeutic Platform on Ulcerative Colitis and Crohn's Disease

Hoth Therapeutics, Inc. announced that it expects to receive $15.000001 million in funding

Hoth Therapeutics, Inc. Provides Update on Novel Peptide COVID-19 Therapeutic HT-002 Preclinical Studies

Hoth Therapeutics, Inc. Completes Site Recruitment for Cohort 1 of First in Human Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis

Hoth Therapeutics Expands Intellectual Property Portfolio with Novel Alzheimer's Treatment

Hoth Therapeutics, Inc. Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Development of HT-001 For Cancer Patients

Hoth Therapeutics' HT-003 Shows Anti-inflammatory Benefits, Hoth to Expand Drug Development to Include Treatment of Inflammatory Bowel Diseases (IBDs)

New 90-day high: US$3.04

Hoth Therapeutics Scientific Advisory Board Member, Michael Peters, Ph.D., Publishes Whitepaper Regarding COVID-19 SARS-CoV-2 in bioRxiv

Voltron Therapeutics, Inc. Initiates Additional Animal Testing of Self-Assembling Vaccine in Fight Against Covid-19

Hoth Therapeutics Partners with Camargo Pharmaceutical Services for the HT-001 IND, a Treatment for Cancer Patients

Hoth Therapeutics, Inc. Provides Operational Update on Novel Therapeutic Pipeline

Hoth provides pipeline and regulatory timeline update

マネジメント基準チェック /44